Kailera Therapeutics Inc (KLRA) FinancialsKLRAKailera Therapeutics Inc

In the context of the broader market, KLRA competes directly with industry leaders such as KRSA and CMPS. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against KRSA's N/A and CMPS's N/A. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Kailera Therapeutics has shown a significant improvement in total equity, rising from -432 million USD in Q1 2026 to 1.118 billion USD in Q2 2026, indicating a turnaround in financial health. However, the company has reported substantial net losses, with Q2 2026 net income at -111.3 million USD.